▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3825 by analyst upside · 2026-09-27
BIIB
Biogen Inc.
Healthcare · Market Cap $34B · P/E 40.7x
ANALYST PRICE TARGET
+4.6%
implied upside to consensus target
Current Price $227.6
Consensus Target $238.18
Bull Target $300.0
Bear Target $175.0
Analysts Covering 31
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
17
Hold
11
Sell
0
52-Week Low $135.39
52-Week High $229.19
YTD Return +28.0%
FUNDAMENTALS
Market Cap $34B
P/E Ratio (TTM) 40.7x
Forward P/E 13.8x
EPS (TTM) $5.59
PEG Ratio 2.35
Dividend Yield N/A
Revenue (TTM) $10.0B
Profit Margin 8.3%
52-WEEK RANGE
52-Week Low $135.39
52-Week High $229.19
Current Price $227.6
Bear Target $175.0
Bull Target $300.0
● Now $227.6 ● Target $238.18
TRADING DATA
Avg Volume 1.1M
YTD Return +28.0%
Analyst Count 31
Consensus Buy
Upside to Target +4.6%
Last Updated 2026-09-27

ANALYST SUMMARY

Biogen Inc. (BIIB) is currently trading at $227.6 with a Wall Street consensus price target of $238.18, implying potential upside of 4.6% over the next 12 months. 31 analysts currently cover BIIB, with a consensus rating of Buy - 65% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $300.0, while the most cautious has a target of $175.0.

BIIB operates in the Healthcare sector with a market capitalisation of $34B. The stock is up 28.0% year-to-date and is currently trading near the upper end of its 52-week range of $135.39 – $229.19.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MTD -3.6%
Mettler-Toledo International Inc.
$30B · P/E 34.1x · Hold
IDXX +35.1%
IDEXX Laboratories, Inc.
$41B · P/E 37.0x · Buy
WST +10.0%
West Pharmaceutical Services, Inc.
$26B · P/E 47.4x · Buy
HLN +28.9%
Haleon plc
$41B · P/E 19.3x · Buy
DXCM +9.1%
DexCom, Inc.
$33B · P/E 34.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BIIB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HSBC - Reiterated
Reduce → Reduce 2026-09-10 Building track record
Piper Sandler reit
Overweight → Overweight 2026-09-03 14% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-25 Building track record
Wolfe Research ↑ Upgrade
Peer Perform → Outperform 2026-08-13 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-08-04 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-08-03 Building track record
UBS - Reiterated
Buy → Buy 2026-07-30 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-07-30 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
26/30
Consensus clarity
19/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →